Profiling mitochondrial DNA mutations in tumors and circulating extracellular vesicles of triple‐negative breast cancer patients for potential biomarker development
FASEB BioAdvances · 2023-10 · 5 (10) · 412-426
DOI: 10.1096/fba.2023-00070 ↗Kurz gefasst
Fachartikel in der Zeitschrift FASEB BioAdvances, online erschienen am 08.09.2023. Verfasst von Kunwar Somesh Vikramdeo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mitchell Cancer Institute, University of South Alabama Mobile Alabama USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Early detection and recurrence prediction are challenging in triple‐negative breast cancer (TNBC) patients. We aimed to develop mitochondrial DNA (mtDNA)‐based liquid biomarkers to improve TNBC management. Mitochondrial genome (MG) enrichment and next‐generation sequencing mapped the entire MG in 73 samples (64 tissues and 9 extracellular vesicles [EV] samples) from 32 metastatic TNBCs. We measured mtDNA and cardiolipin (CL) contents, NDUFB8, and SDHB protein expression in tumors and in corresponding circulating EVs. We identified 168 nonsynonymous mtDNA mutations, with 73% (123/186) coding and 27% (45/168) noncoding in nature. Twenty percent of mutations were nucleotide transversions. Respiratory complex I (RCI) was the key target, which harbored 44% (74/168) of the overall mtDNA mutations. A panel of 11 hotspot mtDNA mutations was identified among 19%–38% TNBCs, which were detectable in the serum‐derived EVs with 82% specificity. Overall, 38% of the metastatic tumor‐signature mtDNA mutations were traceable in the EVs. An appreciable number of mtDNA mutations were homoplasmic (18%, 31/168), novel (14%, 23/168), and potentially pathogenic (9%, 15/168). The overall and RCI‐specific mtDNA mutational load was higher in women with African compared to European ancestry accompanied by an exclusive abundance of respiratory complex (RC) protein NDUFB8 (RCI) and SDHB (RCII) therein. Increased mtDNA ( p < 0.0001) content was recorded in both tumors and EVs along with an abundance of CL ( p = 0.0001) content in the EVs. Aggressive tumor‐signature mtDNA mutation detection and measurement of mtDNA and CL contents in the EVs bear the potential to formulate noninvasive early detection and recurrence prediction strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mitchell Cancer Institute, University of South Alabama Mobile Alabama USA.
- Department of Pathology, College of Medicine University of South Alabama Mobile Alabama USA.
- Department of Mathematics and Statistics University of South Alabama Mobile Alabama USA.
- Department of Biochemistry and Molecular Biology University of South Alabama Mobile Alabama USA.
- Department of Pathology and Laboratory Medicine University of Kansas Medical Center Kansas City Kansas USA.
- The University of Kansas Cancer Center, University of Kansas Medical Center Kansas City Kansas USA.
ORCID-Profile: Kunwar Somesh Vikramdeo, Shashi Anand, Sarabjeet Kour Sudan, Paramahansa Pramanik, Seema Singh, Andrew K Godwin, Ajay Pratap Singh, Santanu Dasgupta
Förderung
- NIGMS NIH HHS
Zitieren
APA
Vikramdeo, K. S., Anand, S., Sudan, S. K., Pramanik, P., Singh, S., Godwin, A. K., Singh, A. P., & Dasgupta, S. (2023). Profiling mitochondrial DNA mutations in tumors and circulating extracellular vesicles of triple‐negative breast cancer patients for potential biomarker development. FASEB BioAdvances, 5(10), 412-426. https://doi.org/10.1096/fba.2023-00070
Vancouver
Vikramdeo KS, Anand S, Sudan SK, Pramanik P, Singh S, Godwin AK, et al. Profiling mitochondrial DNA mutations in tumors and circulating extracellular vesicles of triple‐negative breast cancer patients for potential biomarker development. FASEB BioAdvances. 2023;5(10):412-426. doi:10.1096/fba.2023-00070
BibTeX
@article{Vikramdeo2023,
author = {Vikramdeo, Kunwar Somesh and Anand, Shashi and Sudan, Sarabjeet Kour and Pramanik, Paramahansa and Singh, Seema and Godwin, Andrew K and Singh, Ajay Pratap and Dasgupta, Santanu},
title = {Profiling mitochondrial DNA mutations in tumors and circulating extracellular vesicles of triple‐negative breast cancer patients for potential biomarker development},
journal = {FASEB BioAdvances},
year = {2023},
volume = {5},
number = {10},
pages = {412--426},
doi = {10.1096/fba.2023-00070}
}
EUVIMED